MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Design Therapeutics Inc

Fermé

3.7 1.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.59

Max

3.77

Chiffres clés

By Trading Economics

Revenu

-4.1M

-18M

BPA

-0.31

Employés

56

EBITDA

-3.7M

-20M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+141.48% upside

Dividendes

By Dow Jones

Prochains Résultats

4 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-73M

191M

Ouverture précédente

2.33

Clôture précédente

3.7

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juil. 2025, 23:45 UTC

Acquisitions, Fusions, Rachats

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 juil. 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 23:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 juil. 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3 juil. 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 juil. 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 juil. 2025, 22:21 UTC

Résultats

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 juil. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 juil. 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3 juil. 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 juil. 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious -2-

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 juil. 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3 juil. 2025, 15:47 UTC

Résultats

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 juil. 2025, 15:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

141.48% hausse

Prévisions sur 12 Mois

Moyen 8.5 USD  141.48%

Haut 12 USD

Bas 5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

1

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

3.26 / 3.63Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.